Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
J1356: STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) Vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Protocol Number:
J1356
Phase:
Phase II
Physician:
Nilofer Azad
Purpose:
To determine the benefits of using FOLFOXIRI/Bevacizumab vs FOLFOX/Bevacizumab as first line therapy in treatment naive patients with meatstatic colorectal cancer.
Eligibility:
Metastatic colorectal cancer-no prior systemic treatment for metastatic Colorectal cancer, except palliative radiosesitizer; adjuvant chemotherapy completed less than 12 months prior to study consent-good physical condition with good blood counts and organ function.
Treatment:
Phase II This is a randomized clinical trial that is not blinded. Patients will be randomized to FOLFOX/Bevacizumab, FOLFOXIRI/Bevacizumab or sequential FOLFOXIRI/Bevacizumab(every 2 weeks for 4 months induction phase). Patient has good result and is tolerating the regimen after 4 month will continue for 2 more months. For specific study drug treatment information, please contact Rosalind Walker, RN, at rwalker3@jhmi.edu.
Population:
Adult
Last Update
09/17/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer